美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Silexion Therapeutics Corp

1.04

-0.4650-31.00%

盤後：1.080.0450+4.35%19:59 EDT

成交量：203.06萬

成交額：245.05萬

市值：139.62萬

市盈率：-0.02

高：1.50

開：1.49

低：1.02

收：1.50

52周最高：80.00

52周最低：1.02

股本：134.90萬

流通股本：98.40萬

量比：10.28

換手率：206.36%

股息：- -

股息率：- -

每股收益(TTM):-63.7810

每股收益(LYR):-89.5962

淨資產收益率：-897.46%

總資產收益率：-123.27%

市淨率：4.80

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

Silexion Therapeutics Corp 公布 Sil204 在 KRAS 突變癌細胞中的積極臨床前研究結果

Silexion Therapeutics Corp：以色列與德國新站點將加入Sil204 2/3期臨床試驗

Silexion Therapeutics 在特拉維夫蘇拉斯基醫療中心成功啓動 Sil204 針對局部晚期胰腺癌的 2/3 期臨床試驗

Silexion Therapeutics Corp 宣佈：截至2026年7月29日，已獲以色列Sil204試驗全部監管批准

Maxim集團調整目標價至6美元，反映Silexion Therapeutics 1:10並股

Silexion Therapeutics Corp在德國獲無條件試驗批准，此前倫理委員會給出積極意見

Silexion Therapeutics 公布Sil204針對Kras驅動型胰腺癌免疫療法的積極初步數據

Silexion Therapeutics宣佈啓動Sil204的GMP臨床供應生產，並獲特拉維夫Sourasky醫療中心批准2/3期試驗

Silexion Therapeutics成功向德國BfArM提交Sil204針對KRAS驅動局部晚期胰腺癌的II/III期臨床試驗申請

Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請

Silexion Therapeutics獲以色列衞生部批准啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗

Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.035,"timestamp":1786478400000,"preClose":1.5,"halted":0,"volume":2030572,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.035,"latestTime":"19:59 EDT","volume":1253064,"amount":1601972.28845,"timestamp":1786492795131,"change":0.045,"changeRate":0.043478,"amplitude":0.463865},"delay":0,"changeRate":-0.31000000000000005,"floatShares":983988,"shares":1349000,"eps":-63.78105,"marketStatus":"未開盤","change":-0.465,"latestTime":"08-11 16:00:00 EDT","open":1.49,"high":1.5,"low":1.0201,"amount":2450472.7655368,"amplitude":0.319933,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-63.78105,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1786521600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.5,"preHourTrading":{"tag":"盘前","latestPrice":1.49,"preClose":1.5,"latestTime":"09:25 EDT","volume":4938,"amount":7616.1134364,"timestamp":1786454710016,"change":-0.01,"changeRate":-0.006667,"amplitude":0.074733},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.035,"latestTime":"19:59 EDT","volume":1253064,"amount":1601972.28845,"timestamp":1786492795131,"change":0.045,"changeRate":0.043478,"amplitude":0.463865},"volumeRatio":10.284158},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":983988,"roa":"-123.27%","roe":"-897.46%","lyrEps":-89.596245,"volumeRatio":10.284158,"shares":1349000,"dividePrice":0,"high":1.5,"amplitude":0.319933,"preClose":1.5,"low":1.0201,"week52Low":1.0201,"pbRate":"4.80","week52High":80,"institutionHeld":0,"latestPrice":1.035,"eps":-63.78105,"divideRate":0,"volume":2030572,"delay":0,"ttmEps":-63.78105,"open":1.49,"prevYearClose":19.2,"prevWeekClose":1.87,"prevMonthClose":1.88,"prevQuarterClose":2.55,"fiveDayClose":1.9,"twentyDayClose":2.5,"sixtyDayClose":4.988},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-29","symbol":"SLXN","defaultRemindTime":1780061400000,"type":"split","dateTimestamp":1780027200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1785556800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-08-10","current":-0.016227,"percent":0.987539,"low":-1.070842,"twenty":-0.533832,"median":-0.293157,"eighty":-0.11317,"high":-0.051928,"avg":-0.342612,"sd":0.240503,"marketCap":783520},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-17","current":-0.279616,"twenty":-0.584956,"median":-0.417583,"eighty":-0.131655,"marketCap":3330785},{"date":"2026-04-24","current":-0.257275,"twenty":-0.583604,"median":-0.415793,"eighty":-0.131962,"marketCap":3064655},{"date":"2026-05-01","current":-0.171153,"twenty":-0.571093,"median":-0.415025,"eighty":-0.132167,"marketCap":2038773},{"date":"2026-05-08","current":-0.145121,"twenty":-0.564344,"median":-0.413413,"eighty":-0.133702,"marketCap":1728677},{"date":"2026-05-15","current":-0.139472,"twenty":-0.562336,"median":-0.409651,"eighty":-0.135442,"marketCap":1661395},{"date":"2026-05-22","current":-0.12255,"twenty":-0.558738,"median":-0.40296,"eighty":-0.131962,"marketCap":1582122},{"date":"2026-05-29","current":-0.138778,"twenty":-0.557906,"median":-0.397852,"eighty":-0.132133,"marketCap":1791622},{"date":"2026-06-05","current":-0.160977,"twenty":-0.557906,"median":-0.386196,"eighty":-0.133327,"marketCap":2078215},{"date":"2026-06-12","current":-0.100286,"twenty":-0.557906,"median":-0.370491,"eighty":-0.132133,"marketCap":1294694},{"date":"2026-06-18","current":-0.09412,"twenty":-0.552496,"median":-0.356785,"eighty":-0.130188,"marketCap":1215085},{"date":"2026-06-26","current":-0.088602,"twenty":-0.543705,"median":-0.341131,"eighty":-0.128209,"marketCap":1143856},{"date":"2026-07-02","current":-0.083896,"twenty":-0.541677,"median":-0.338335,"eighty":-0.124456,"marketCap":1083102},{"date":"2026-07-10","current":-0.084708,"twenty":-0.536943,"median":-0.320891,"eighty":-0.122887,"marketCap":1093576},{"date":"2026-07-17","current":-0.090225,"twenty":-0.534237,"median":-0.31317,"eighty":-0.120908,"marketCap":1164806},{"date":"2026-07-24","current":-0.077243,"twenty":-0.534237,"median":-0.309392,"eighty":-0.118588,"marketCap":997208},{"date":"2026-07-31","current":-0.059717,"twenty":-0.534237,"median":-0.302127,"eighty":-0.117019,"marketCap":770950},{"date":"2026-08-07","current":-0.058095,"twenty":-0.534237,"median":-0.293597,"eighty":-0.113607,"marketCap":750001},{"date":"2026-08-10","current":-0.060691,"twenty":-0.533832,"median":-0.293157,"eighty":-0.11317,"marketCap":783520}],"updateTime":1786478604936},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1105446011","title":"Silexion Therapeutics Corp 公布 Sil204 在 KRAS 突變癌細胞中的積極臨床前研究結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1105446011","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105446011?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849395,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其在针对 KRAS 突变癌细胞的研究中，取得了关于 Sil204 的积极临床前发现。这一成果为后续的研发工作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197854807","title":"Silexion Therapeutics Corp：以色列與德國新站點將加入Sil204 2/3期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1197854807","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197854807?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:06","pubTimestamp":1785323184,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp披露，预计在未来数月内，将有更多来自以色列和德国的研究中心加入其Sil204 2/3期临床试验项目。这一举措旨在进一步扩大试验的地域覆盖范围，并推动候选药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195302666","title":"Silexion Therapeutics 在特拉維夫蘇拉斯基醫療中心成功啓動 Sil204 針對局部晚期胰腺癌的 2/3 期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1195302666","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195302666?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322910,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics（SLXN）已成功在特拉维夫苏拉斯基医疗中心启动旗下药物 Sil204 的 2/3 期临床试验。该试验聚焦于局部晚期胰腺癌患者，标志着该公司在肿瘤治疗领域迈出关键一步。此次启动不仅验证了前期研究的积累，也为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191362943","title":"Silexion Therapeutics Corp 宣佈：截至2026年7月29日，已獲以色列Sil204試驗全部監管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1191362943","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191362943?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322907,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 正式通报，截至2026年7月29日，该公司已成功获得在以色列开展Sil204试验所需的所有监管批准。这一里程碑式的进展，标志着其研发管线向前迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161346049","title":"Maxim集團調整目標價至6美元，反映Silexion Therapeutics 1:10並股","url":"https://stock-news.laohu8.com/highlight/detail?id=1161346049","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161346049?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 13:41","pubTimestamp":1782279675,"startTime":"0","endTime":"0","summary":"Maxim集团调整了Silexion Therapeutics Corp的目标股价。该机构将目标价从60美元下调至6美元，此举旨在反映公司近期完成的1:10反向股票分割。反向股票分割导致流通股数量减少，每股价格相应调整，因此目标价需进行同步修正以保持可比性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134010182","title":"Silexion Therapeutics Corp在德國獲無條件試驗批准，此前倫理委員會給出積極意見","url":"https://stock-news.laohu8.com/highlight/detail?id=1134010182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134010182?lang=zh_tw&edition=fundamental","pubTime":"2026-06-23 20:41","pubTimestamp":1782218479,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，其在德国的临床试验已获无条件批准。这一决定基于德国伦理委员会此前出具的积极意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158403906","title":"Silexion Therapeutics 公布Sil204針對Kras驅動型胰腺癌免疫療法的積極初步數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1158403906","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158403906?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 21:28","pubTimestamp":1778765302,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其针对Kras驱动型胰腺癌的免疫疗法候选药物Sil204，取得了积极的初步研究结果。这一发现为这一难治性癌症领域的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187044421","title":"Silexion Therapeutics宣佈啓動Sil204的GMP臨床供應生產，並獲特拉維夫Sourasky醫療中心批准2/3期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1187044421","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187044421?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 20:02","pubTimestamp":1778673723,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics公司宣布，已与一家领先的全球合同开发与生产组织（CDMO）合作，启动了其候选药物Sil204的GMP临床供应生产。与此同时，公司还获得了来自以色列特拉维夫Sourasky医疗中心对其Sil204药物进行2/3期临床试验的新批准。这两项进展标志着该药物临床开发路径上的重要里程碑，为其后续的临床研究推进提供了关键的物料支持和试验场地保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194280405","title":"Silexion Therapeutics成功向德國BfArM提交Sil204針對KRAS驅動局部晚期胰腺癌的II/III期臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1194280405","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194280405?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 20:48","pubTimestamp":1777380512,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp（简称SLXN）宣布，已顺利完成其核心候选药物Sil204针对KRAS基因驱动型局部晚期胰腺癌的II/III期临床试验申请，并正式提交至德国联邦药品和医疗器械研究所（BfArM）。这一关键进展标志着该创新疗法向临床验证迈出重要一步，为全球胰腺癌患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128273196","title":"Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1128273196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128273196?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:39","pubTimestamp":1774355952,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外，公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158550340","title":"Silexion Therapeutics獲以色列衞生部批准 啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158550340?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:38","pubTimestamp":1774355925,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp已正式获得以色列卫生部批准，将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步，为评估其在治疗这一难治性癌症方面的潜力铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112627847","title":"Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112627847","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112627847?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 05:02","pubTimestamp":1773781344,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp公布了2025年第四季度及全年的财务业绩，并同步更新了公司最新的业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}